Intralytix, Inc.

Johns Hopkins University

Other

Vanderbilt University

Asklepion Pharmaceuticals, LLC

Alpharma, LLC

Gary R Pasternack

Alexander Sulakvelidze

Francis P Kuhajda

Craig Arthur Townsend

J Glenn Morris

Zemphira Alavidze

Torrey C Brown

James D Dick

Nicole M Parrish

Marshall Lynn Summar

Frederick E Barr

John Voneiff

Jay Frederick Gibson

Neelakandha S Mani

Gurdyal Kalsi

Gerald J Kocheavar

Jonathan R Brody

Alexander Sulakelidze

Shanmuga Sozhamamnnan

Shrihari S Kadkol

Craig A Townsend

Torrey Brown

This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally. The intermediate phase may be while the patient's breathing is being assisted mechanically.

Action of L-citrulline to prevent or treat endothelial dysfunction

The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains ofspecies, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth ofspecies in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).

bacteriophages and uses thereof

The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains ofspecies, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth ofspecies in various settings (e.g., food safety, sanitation, probiotics).

Salmonella bacteriophage and uses thereof

[object Object]

The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Reduction in bacterial colonization by administering bacteriophage compositions

The present invention is directed to isolated bacteriophage having strong lytic activity against strains ofin particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth ofin various settings.

The present invention is directed to isolatedbacteriophage, and methods of usingbacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by. The present invention also contemplates the use ofbacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by

The present invention is directed to isolated bacteriophage having strong lytic activity against strains ofO157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth ofO157:H7 in various settings.

The present invention is directed to isolated bacteriophage having strong lytic activity against strains of, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth ofin various settings.

Growing community of inventors

Baltimore, MD, United States of America

Gary R Pasternack